266 related articles for article (PubMed ID: 33310293)
1. The impact of neoadjuvant systemic therapy on breast conservation rates in patients with HER2-positive breast cancer: Surgical results from a phase II randomized controlled trial.
Yamaguchi T; Hozumi Y; Sagara Y; Takahashi M; Yoneyama K; Fujisawa T; Osumi S; Akabane H; Nishimura R; Mieno MN; Mukai H
Surg Oncol; 2021 Mar; 36():51-55. PubMed ID: 33310293
[TBL] [Abstract][Full Text] [Related]
2. Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance).
Golshan M; Cirrincione CT; Sikov WM; Carey LA; Berry DA; Overmoyer B; Henry NL; Somlo G; Port E; Burstein HJ; Hudis C; Winer E; Ollila DW;
Breast Cancer Res Treat; 2016 Nov; 160(2):297-304. PubMed ID: 27704226
[TBL] [Abstract][Full Text] [Related]
3. Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance).
Golshan M; Cirrincione CT; Sikov WM; Berry DA; Jasinski S; Weisberg TF; Somlo G; Hudis C; Winer E; Ollila DW;
Ann Surg; 2015 Sep; 262(3):434-9; discussion 438-9. PubMed ID: 26222764
[TBL] [Abstract][Full Text] [Related]
4. Conversion rate from mastectomy to breast conservation after neoadjuvant dual target therapy for HER2-positive breast cancer in the Asian population.
Chang YK; Co M; Kwong A
Breast Cancer; 2020 May; 27(3):456-463. PubMed ID: 31916189
[TBL] [Abstract][Full Text] [Related]
5. Breast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Surgical Results From the BrighTNess Randomized Clinical Trial.
Golshan M; Loibl S; Wong SM; Houber JB; O'Shaughnessy J; Rugo HS; Wolmark N; McKee MD; Maag D; Sullivan DM; Metzger-Filho O; Von Minckwitz G; Geyer CE; Sikov WM; Untch M
JAMA Surg; 2020 Mar; 155(3):e195410. PubMed ID: 31913413
[TBL] [Abstract][Full Text] [Related]
6. Impact of neoadjuvant chemotherapy and pathological complete response on eligibility for breast-conserving surgery in patients with early breast cancer: A meta-analysis.
Criscitiello C; Golshan M; Barry WT; Viale G; Wong S; Santangelo M; Curigliano G
Eur J Cancer; 2018 Jul; 97():1-6. PubMed ID: 29734046
[TBL] [Abstract][Full Text] [Related]
7. Locoregional Control According to Breast Cancer Subtype and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Undergoing Breast-conserving Therapy.
Swisher SK; Vila J; Tucker SL; Bedrosian I; Shaitelman SF; Litton JK; Smith BD; Caudle AS; Kuerer HM; Mittendorf EA
Ann Surg Oncol; 2016 Mar; 23(3):749-56. PubMed ID: 26511263
[TBL] [Abstract][Full Text] [Related]
8. Pathologic Complete Response Rates After Neoadjuvant Pertuzumab and Trastuzumab with Chemotherapy in Early Stage HER2-Positive Breast Cancer - Increasing Rates of Breast Conserving Surgery: A Real-World Experience.
Boér K; Kahán Z; Landherr L; Csőszi T; Máhr K; Ruzsa Á; Horváth Z; Budai B; Rubovszky G
Pathol Oncol Res; 2021; 27():1609785. PubMed ID: 34257621
[No Abstract] [Full Text] [Related]
9. Impact of Neoadjuvant Paclitaxel/Trastuzumab/Pertuzumab on Breast Tumor Downsizing for Patients with HER2+ Breast Cancer: Single-Arm Prospective Clinical Trial.
Weiss A; Li T; Desai NV; Tung NM; Poorvu PD; Partridge AH; Nakhlis F; Dominici L; Sinclair N; Spring LM; Faggen M; Constantine M; Krop IE; DeMeo M; Wrabel E; Alberti J; Chikarmane S; Tayob N; King TA; Tolaney SM; Winer EP; Mittendorf EA; Waks AG
J Am Coll Surg; 2023 Aug; 237(2):247-256. PubMed ID: 37194964
[TBL] [Abstract][Full Text] [Related]
10. Breast-Conserving Therapy in Patients with cT3 Breast Cancer with Good Response to Neoadjuvant Systemic Therapy Results in Excellent Local Control: A Comprehensive Cancer Center Experience.
van der Noordaa MEM; Ioan I; Rutgers EJ; van Werkhoven E; Loo CE; Voorthuis R; Wesseling J; van Urk J; Wiersma T; Dezentje V; Vrancken Peeters MTFD; van Duijnhoven FH
Ann Surg Oncol; 2021 Nov; 28(12):7383-7394. PubMed ID: 33978889
[TBL] [Abstract][Full Text] [Related]
11. A prospective trial of preoperative chemotherapy in resectable breast cancer: predictors of breast-conservation therapy feasibility.
Newman LA; Buzdar AU; Singletary SE; Kuerer HM; Buchholz T; Ames FC; Ross MI; Hunt KK
Ann Surg Oncol; 2002 Apr; 9(3):228-34. PubMed ID: 11923128
[TBL] [Abstract][Full Text] [Related]
12. Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.
Semiglazov V; Eiermann W; Zambetti M; Manikhas A; Bozhok A; Lluch A; Tjulandin S; Sabadell MD; Caballero A; Valagussa P; Baselga J; Gianni L
Eur J Surg Oncol; 2011 Oct; 37(10):856-63. PubMed ID: 21843921
[TBL] [Abstract][Full Text] [Related]
13. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy.
Caudle AS; Yu TK; Tucker SL; Bedrosian I; Litton JK; Gonzalez-Angulo AM; Hoffman K; Meric-Bernstam F; Hunt KK; Buchholz TA; Mittendorf EA
Breast Cancer Res; 2012 May; 14(3):R83. PubMed ID: 22621334
[TBL] [Abstract][Full Text] [Related]
14. Systemic Therapy Advances for HER2-Positive and Triple Negative Breast Cancer: What the Surgeon Needs to Know.
Downs-Canner S; Weiss A
Clin Breast Cancer; 2024 Jun; 24(4):328-336. PubMed ID: 38616443
[TBL] [Abstract][Full Text] [Related]
15. Do MRI and mammography reliably identify candidates for breast conservation after neoadjuvant chemotherapy?
Jochelson MS; Lampen-Sachar K; Gibbons G; Dang C; Lake D; Morris EA; Morrow M
Ann Surg Oncol; 2015 May; 22(5):1490-5. PubMed ID: 25777093
[TBL] [Abstract][Full Text] [Related]
16. Axillary response according to neoadjuvant single or dual human epidermal growth factor receptor 2 (HER2) blockade in clinically node-positive, HER2-positive breast cancer.
Cha C; Ahn SG; Kim D; Lee J; Park S; Bae SJ; Kim JY; Park HS; Park S; Kim SI; Park BW; Jeong J
Int J Cancer; 2021 Oct; 149(8):1585-1592. PubMed ID: 34213778
[TBL] [Abstract][Full Text] [Related]
17. Margins in Breast-Conserving Surgery After Neoadjuvant Therapy.
Choi J; Laws A; Hu J; Barry W; Golshan M; King T
Ann Surg Oncol; 2018 Nov; 25(12):3541-3547. PubMed ID: 30128902
[TBL] [Abstract][Full Text] [Related]
18. Risk of Positive Sentinel Lymph Node After Neoadjuvant Systemic Therapy in Clinically Node-Negative Breast Cancer: Implications for Postmastectomy Radiation Therapy and Immediate Breast Reconstruction.
Samiei S; van Kaathoven BN; Boersma L; Granzier RWY; Siesling S; Engelen SME; de Munck L; van Kuijk SMJ; van der Hulst RRJW; Lobbes MBI; Smidt ML; van Nijnatten TJA
Ann Surg Oncol; 2019 Nov; 26(12):3902-3909. PubMed ID: 31359276
[TBL] [Abstract][Full Text] [Related]
19. De-escalation of axillary surgery in breast cancer patients treated in the neoadjuvant setting: a Dutch population-based study.
Simons JM; Koppert LB; Luiten EJT; van der Pol CC; Samiei S; de Wilt JHW; Siesling S; Smidt ML
Breast Cancer Res Treat; 2020 Apr; 180(3):725-733. PubMed ID: 32180074
[TBL] [Abstract][Full Text] [Related]
20. Conservative surgery after neoadjuvant chemotherapy in patients with operable breast cancer.
Franceschini G; Di Leone A; Natale M; Sanchez MA; Masett R
Ann Ital Chir; 2018; 89():290. PubMed ID: 30352955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]